After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.

Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.